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Simniauy Details of 1123 patients registered in Scotland between 1983 and 1990 for testicular cancer under
the Scottish Cancer Registration Scheme were obtained and compared with registrations within the five
Scottish oncology centres. Some registration discrepancies were identified. Twenty-eight cancer registrations
(2.5%) were coded to the wrong site. 29 patients seen at oncology centres had no cancer registration and 14
cancer registrations had the wrong histology. Five hundred and twenty-seven patients with testicular non-
seminomatous germ cell tumours (NSGCT) and 567 with testicular seminoma were identified. Referral rates to
specialist oncology centres for testicular germ cell tumours were measured by period and health board area of
residence. For the whole study period 92% of NSGCT and 93% of seminoma patients were referred to
specialist centres for treatment. Referral rates for different health board areas of residence were not
significantly different. This study shows that within Scotland the majority of patients with testicular NSGCT
and seminoma are referred to specialist centres. and suggests referral rates of around 92% are underestimates.
Access is not related to area of residence.
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Testicular germ cell tumours are now the commonest cancer
in men aged under 40 in Scotland (Sharp et al., 1993a) and
the incidence is increasing. The age-standardised incidence
rates in Scotland for the most recent years available 1988-90
are 2.3 per 100 000 for NSGCT and 2.9 per 100 000 for
seminoma, both having risen from 1.8 per 100 000 for
1975-77 (Sharp et al., 1993b). Effective chemotherapy has
transformed NSGCT from what was invariably a fatal
disease, once it had metastasised, to one which is usually
curable (Ellis and Sikora, 1987). Similarly, the majority of
patients with seminoma are now curable with radiotherapy
or chemotherapy (Pizzocaro, 1989). For the whole of Scot-
land 5 year survival rates of 85.0% and 94.5% have been
reported for NSGCT and seminoma, respectively, for the
period 1983- 1987 (Sharp et al., 1993b).
Cure rates may be related to the ability to give effective
treatment (Stiller, 1994), and for NSGCT in the West of
Scotland it has been suggested that results are better when
there is a particular expertise in the treatment of the disease,
with centres seeing more patients performing better (Harding,
1993).
Given this background of increasing incidence and the
suggestion that cure rates may vary according to the exper-
tise available, a study on referral of testicular NSGCT and
seminoma patients to specialist centres within Scotland has
been performed. This study was a precursor to a national
audit examining treatment policies, survival and reasons for
mortality in patients with NSGCr. Results from this audit
are reported in the accompanying papers (Howard et al.,
1995a,b).
Methods
Details of all new cancer registrations for cancer of the testis
were obtained from the Scottish Cancer Registration Scheme
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for the period 1 January 1983 to 31 December 1990. These
cancer registrations were then compared with registrations at
the five Scottish oncology centres. A referred case was
defined as an oncology centre registration if they had been
seen at the centre, or by a specialist associated with the
centre.
To perform the comparison oncology centres provided
either computer listings of testis cancer cases, or allowed
their patient registers and casenotes to be examined. In this
way study groups were identified and referral rates to
specialist centres measured. For NSGCT only, casenotes for
two sub-groups, all new cases in 1989 and all deaths amongst
new registrations between 1988 and 1990, were examined
more closely as these were the patients for the accompanying
audits (Howard et at., 1995a,b).
For the area of residence analysis the numbers in some
health boards of residence at diagnosis of cancer were small
so were grouped crudely according to population density. A
priori the following groupings were defined
(1) urban - Ayrshire and Arran, Argyll and Clyde. Fife,
Forth Valley, Lanarkshire and Tayside;
(2) rural - Borders, Dumfries and Galloway. Grampian,
Highland, Orkney, Shetland and Western Isles.
Greater Glasgow and Lothian health board areas were
examined separately.
Results
A total of 1123 cases of cancer of the testis were recorded
under the Scottish Cancer Registration Scheme between 1983
and 1990. Comparison with registrations at specialist on-
cology centres and review of casenotes showed that of these,
28 were inappropriately registered. A further 14 cases had
been coded to the wrong histological group and were recoded
to the appropriate group. Conversely 29 cases were recorded
at oncology centres, but not included amongst cancer regis-
trations. Thus 527 cases of NSGCT and 567 cases of
seminoma, were identified and included in the study group.Tesculargamcal btomos and rde.l bspecda oumag ca*es inScoand
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Table I Referrals to oncology centres among new registrations for testicular NSGCT
and seminoma Scotland 1983-90
Period NSGCT Seminoma
treatment Number Total Percentage Number Total Percentage
commenced referred registered referred referred registered referred
1983 -86 240 265 91 230 248 93
1987-90 245 262 94 298 319 93
All vears 485 527 92 528 567 93
Table H Referrals to oncology centres among new registrations for testicular
NSGCT and seminoma Scotland 1983-90
NSGCT Seminoma
Number Total Percentage Number Total Percentage
RegistrY referred registered referred referred registered referred
A 21 24 88 '2 23 96
B 61 63 97 71 75 95
C 28 29 97 51 52 98
D 106 122 87 129 142 91
E 269 289 93 255 275 93
Total 485 527 92 528 567 93
Table m Referrals to oncology centres by health board area of residence among new
registrations for testicular NSGCT and seminoma Scotland 1983-90
.VSGCT Seminoma
Health board Number Total Percentage Number Total Percentage
area of residence referred registered referred referred registered referred
Greater Glasgow 109 118 92 89 94 95
Lothian 70 80 88 74 80 93
Urban 203 218 93 235 253 93
Rural 101 109 93 128 138 93
NK 2 2 100 2 2 100
Total 485 527 92 528 567 93
The remaining 30 registrations were non-germ-cell tumours
and were excluded from the analysis.
For the complete study period 92% of patients with
NSGCT and 93% with seminoma were referred to clinicians
associated with or working within one of the five oncology
centres (Table I). The number of patients referred to
oncology centres has not notably changed over the study
period.
There are no statistically significant differences in referral
rate for both NSGCT and seminoma between the five Scot-
tish regional cancer registries (NSGCT, xi = 8.30, d.f. =4,
P>0.05; seminoma, X' = 3.72, d.f. = 4, P>0.I0; this test
should be interpreted with caution owing to the relatively
small number of cases involved) (Table II). Similarly there
are no statistical differences between health board areas of
residence at diagnosis (NSGCT. 72 = 2.66, d.f. = 3, P>0.1;
seminoma X = 0.46, d.f. = 3, P>0.5) (Table III). The refer-
ral rate for NSGCT in Lothian health board area is notably
lower, but if the study period is divided into two it increases
in the second half to nearer that for the rest of Scotland
(1987-90: Lothian Health Board 91.5%; rest of Scotland
94.0%).
Discsin
The source data for this study were Scottish cancer registra-
-tions and oncology centre registrations. A total of 28 out of
1123 (2.5%) of cancer registrations were inappropriately
registered as testicular cancer. All diagnoses of patients
treated at oncology centres were confirmed or amended, but
76 non-referrals treated in hospitals throughout Scotland not
required for the casenote reviews reported in the accompany-
ing papers (Howard et al., 1995a,b) did not have their diag-
nosis validated. Even allowing for some non-referrals not
being testis cancer the percentage of site coding errors com-
pares favourably with the rate reported in a recent study of
accuracy of Scottish cancer registrations. In the accuracy
study 5.4% of a random sample of all 1990 registrations had
been coded to the wrong site (Brewster et al., 1994).
Twenty-nine cases at oncology centres had never been
registered as cancer registrations and a further 14 cases had
been allocated the wrong histology. The main reasons for the
missed cancer registrations or changes to histology were
updating of diagnoses or histology, and 'non-standard' refer-
ral to hospital (e.g. from prison or a private hospital).
Inclusion of information from the two casenote NSGCT
reviews detailed in the methods section should not have
affected consistency of data quality between tumour types to
a notable extent. The estimated increase in NSGCT referral
rate arising from the casenote reviews was 2%. More impor-
tant for this study than data quality consistency is the
presence of underregistration at oncology centres which sug-
gests overall referral rates in this paper are underestimates.
It has been suggested referral to specialist centres conveys
an advantage in outcome (Harding et al., 1993; Stiller, 1994).
Referral rates to oncology centres of 92% for NSGCT and
93% for seminoma patients are probably an underestimate.
It is encouraging to note that there were no statistically
significant differences in referral rates between grouped
health board areas of residence. Rates within cancer registry
area, which crudely equate with catchment area for oncology
centre, also showed no statistically signficant differences but
the test may be unreliable due to small numbers in three
registries. These findings suggest that referral rates are similar
throughout Scotland and that rural patients have the same
access as other patients.
It may be that some patients are genuinely not referred to
clinicians in Scottish oncology centres. One possible explana-Teskidr germ cel tuows u de. b spedaak ofnc ceu-es in Scndua
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tion is that men resident and working in Scotland at diag-
nosis seek therapy outwith Scotland near the 'family' home.
This hypothesis is based on some of the inappropriate cancer
registrations reported above, including patients who were not
normally resident in Scotland but had returned 'home' for
therapy. Three residents of health boards close to the English
borders had their cancer registered from an English hospital.
It may be these three patients were treated within specialist
oncology centres in England. Other explanations for non-
registration are patients presenting with advanced disease
who do not survive long enough for referral, while others
may be discussed with oncologists but are not formally
registered due to other medical conditions.
This audit suggests that at least 92% of NSGCT and 93%
of seminoma patients are referred to specialist centres for
treatment, that referral does not depend on where patients
live and rates reported are thought to be underestimates.
This is an important finding considering reports (Harding et
al., 1993; Stiller, 1994) which suggest therapy is better in
specialist oncology centres or where treatment is centralised.
The following papers examine survival and audit therapy
within the five Scottish oncology centres (Howard et al.,
1995a,b).
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